Disposition and metabolism of [


Journal

Xenobiotica; the fate of foreign compounds in biological systems
ISSN: 1366-5928
Titre abrégé: Xenobiotica
Pays: England
ID NLM: 1306665

Informations de publication

Date de publication:
Jun 2019
Historique:
pubmed: 29 5 2018
medline: 13 9 2019
entrez: 29 5 2018
Statut: ppublish

Résumé

The disposition and metabolism of lemborexant, a novel dual orexin receptor antagonist currently under development as a therapeutic agent for insomnia disorder, were evaluated after a single oral administration of [

Identifiants

pubmed: 29806508
doi: 10.1080/00498254.2018.1482509
doi:

Substances chimiques

Orexin Receptor Antagonists 0
Pyridines 0
Pyrimidines 0
Sleep Aids, Pharmaceutical 0
lemborexant 0K5743G68X

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

688-697

Auteurs

Takashi Ueno (T)

a Drug Metabolism and Pharmacokinetics , Eisai Co., Ltd , Tsukuba , Ibaraki , Japan.

Tomomi Ishida (T)

a Drug Metabolism and Pharmacokinetics , Eisai Co., Ltd , Tsukuba , Ibaraki , Japan.

Kazutomi Kusano (K)

a Drug Metabolism and Pharmacokinetics , Eisai Co., Ltd , Tsukuba , Ibaraki , Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH